These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 15032571)
1. The BCR-ABL story: bench to bedside and back. Wong S; Witte ON Annu Rev Immunol; 2004; 22():247-306. PubMed ID: 15032571 [TBL] [Abstract][Full Text] [Related]
2. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. von Bubnoff N; Peschel C; Duyster J Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693 [TBL] [Abstract][Full Text] [Related]
13. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169 [TBL] [Abstract][Full Text] [Related]
14. Important therapeutic targets in chronic myelogenous leukemia. Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563 [TBL] [Abstract][Full Text] [Related]
16. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431 [TBL] [Abstract][Full Text] [Related]
17. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
18. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies]. Nasr R; Bazarbachi A Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097 [TBL] [Abstract][Full Text] [Related]
19. Hematological and molecular response evaluation of CML patients on imatinib. Gupta A; Prasad K J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739 [TBL] [Abstract][Full Text] [Related]